Repositorio Dspace

Emerging concepts in heart failure management and treatment: focus on current guideline-directed medical therapy for heart failure with reduced ejection fraction

Mostrar el registro sencillo del ítem

dc.contributor.author Ospina González, Oscar Eduardo
dc.contributor.author Llanos Mejía, Diana Catalina
dc.contributor.author Kaplinsky, Edgardo
dc.contributor.author Barbagelata, Alejandro
dc.contributor.author Perrone, Sergio Víctor
dc.date.accessioned 2023-08-29T17:35:59Z
dc.date.available 2023-08-29T17:35:59Z
dc.date.issued 2023-01-04
dc.identifier.citation Ospina González, O.E., Llanos Mejía, D.C., Kaplinsky, E., Barbagelata, A., Perrone, S., 2023. Emerging concepts in heart failure management and treatment: focus on current guideline-directed medical therapy for heart failure with reduced ejection fraction. Drugs Context 12, 2022-6–4. https://doi.org/10.7573/dic.2022-6-4 es_ES
dc.identifier.uri https://doi.org/10.7573/dic.2022-6-4
dc.identifier.uri https://repositorio.fleni.org.ar/xmlui/handle/123456789/816
dc.description.abstract ne of the most relevant and differentiating aspects provided by the 2021 European Society of Cardiology guidelines for the diagnosis and treatment of acute and chronic heart failure is the retraction of the historical stepped and vertical pharmacological treatment scheme for heart failure with reduced ejection fraction (HFrEF). Subsequently, it was replaced by an updated algorithm that places four therapeutic families in the same initial horizontal step with an equally high degree of recommendation (class I). In this context, these four pillars, which have demonstrated a significant reduction in mortality and hospitalizations in patients with HFrEF, include (1) angiotensin-converting enzyme inhibitors (ACEi)/angiotensin receptor blockers (ARB)/angiotensin II receptor-neprilysin inhibitors (ARNi), (2) beta blockers, (3) mineralocorticoid receptor antagonists (MRA) and (4) sodium-glucose cotransporter 2 inhibitors (SGLT2is) as the main novelty. This manuscript reviews the current therapeutic algorithm with a special focus on the therapeutic value of adding an MRA (still underused in both clinical trials and real world), changing an ACEi/ARB for an ARNi and incorporating an SGLT2i in patients with HFrEF. This article is part of the Emerging concepts in heart failure management and treatment Special Issue: https://www.drugsincontext.com/special_issues/emerging-concepts-in-heart-failure-management-and-treatment. es_ES
dc.language.iso eng es_ES
dc.publisher Bioexcel Publishing es_ES
dc.rights info:eu-repo/semantics/openAccess
dc.subject Insuficiencia Cardíaca es_ES
dc.subject Heart Failure es_ES
dc.subject Angiotensin-Converting Enzyme Inhibitors es_ES
dc.subject Inhibidores de la Enzima Convertidora de Angiotensina es_ES
dc.subject Adrenergic beta-Antagonists es_ES
dc.subject Antagonistas Adrenérgicos beta es_ES
dc.subject Antagonistas de Receptores de Mineralocorticoides es_ES
dc.subject Mineralocorticoid Receptor Antagonists es_ES
dc.subject odium-Glucose Transport Proteins es_ES
dc.subject Proteínas de Transporte de Sodio-Glucosa es_ES
dc.title Emerging concepts in heart failure management and treatment: focus on current guideline-directed medical therapy for heart failure with reduced ejection fraction es_ES
dc.type info:eu-repo/semantics/article es_ES
dc.type info:eu-repo/semantics/publishedVersion
dc.description.fil Fil: Perrone, Sergio Victor. Fleni. Departamento de Neurología. Servicio de Cardiología; Argentina.
dc.relation.ispartofVOLUME 12
dc.relation.ispartofCOUNTRY Reino Unido
dc.relation.ispartofCITY Londres
dc.relation.ispartofTITLE Drugs in context
dc.relation.ispartofISSN 1740-4398
dc.type.snrd info:ar-repo/semantics/artículo es_ES


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Buscar en DSpace


Listar

Mi cuenta

Estadísticas